Upregulation of ADAM10 in Oral Squamous Cell Carcinoma and its correlation with EGFR, Neoangiogenesis and Clinicopathologic Factors

Publication date: Available online 19 July 2019Source: Journal of Cranio-Maxillofacial SurgeryAuthor(s): Shahroo Etemad-Moghadam, Mojgan AlaeddiniSummaryADAM10 (a disintegrin and metalloproteinase-10) is a known sheddase for EGFR (epidermal growth factor receptor) ligands and has been suggested to modulate angiogenesis. We aimed to evaluate the expression of ADAM10 in patients with oral squamous cell carcinoma (OSCC) and to determine its correlation with EGFR, CD105 and clinicopathologic parameters. Fifty primary OSCCs with clinical data were graded according to the histologic risk assessment (HRA) model and subjected to immunohistechemical staining using antibodies against ADAM10, EGFR1 and CD105. ADAM10 was assessed in both epithelial and stromal components. The associations among all three proteins and clinicopathologic factors including tumor size, lymph node status and distant metastasis (TNM) were statistically analyzed (P<0.05). Epithelial-ADAM10, stromal-ADAM10 and EGFR were overexpressed in 92%, 40% and 56% of the OSCCs, respectively. EGFR expression occurred in peripheral and diffuse patterns, which were also separately considered in our analyses. A significant correlation was found between ADAM10 and CD105 (r=-0.455; P<0.001). Lymphocytic infiltration scores (P=0.04) and tumor size (P=0.001) showed significant differences between EGFR+ and EGFR– tumors, but none of the other variables had any relationships with either clinicopathologic factors or each oth...
Source: Journal of Cranio Maxillofacial Surgery - Category: ENT & OMF Source Type: research